Choudhry’s innovative work in the field of retinal ophthalmology has also been published on the covers of numerous journals further earning him the distinction of a pioneer in retinal imaging.ĭr. ![]() He has published distinguished journals such as The New England Journal of Medicine, the Lancet, Ophthalmology and the Retina Journal. He was the first to pioneer OCT imaging of the peripheral retina and is actively developing novel devices for imaging the retina and vitreous using non-invasive technology. He is considered to be a thought leader in retinal imaging and the diagnosis and treatment of rare disorders of the retina and vitreous. Choudhry is an internationally recognized Vitreoretinal Surgeon with affiliations at both the University of Toronto and Harvard Medical School. At 6 weeks after PVL, there was a complete closure of the MH with BSCVA recovery to 20/30 in the left eye ( E).Dr. At 4 weeks after PVL, there was a decrease in the outer foveal defect ( D). There was a partial lucency of the outer fovea, corresponding to the residual outer foveal defect, in the right eye. At 4 days after receiving 0.3 mL of C 3F 8 gas injection and face-down positioning, a PVD with closure of the inner layers of the MH developed ( C). The BSCVA was deteriorated to 20/100 in the right eye. Within 24 hours after ocriplasmin injection, he reported further visual loss and an urgent examination showed residual VMT and the progressing of the Stage 1 impending MH to a Stage 2 full-thickness MH with residual VMT in the right eye ( B). He elected to undergo ocriplasmin injection. The SD-OCT showed central vitreomacular adhesion only without symptoms in his right eye, but symptomatic central VMT associated with a partial split of the foveal layers, consistent with a Stage 1 impending MH in the left eye ( A). More studies are needed to elucidate its indications, benefits, and risks.Ī 67-year-old man complained of progressive central visual deficit of his left eye in August 2013. Pneumatic vitreolysis with limited face-down position is a viable option for treating VMT with few adverse events. One VMT-only eye formed a MH and another VMT-only eye developed a retinal detachment. Results using logistic regression also showed younger age (P = 0.012), followed by better baseline best spectacle-corrected visual acuity (P = 0.044), lack of diabetes mellitus (P = 0.077), and female gender (P = 0.045) to be predictors of increased VMT release. Univariate analysis showed increased VMT release for eyes with VMT extent within 1 disk area (χ = 13.1, P = 0.002), eyes with absence of diabetes mellitus (χ = 8.8, P = 0.007), and eyes with Stage 2 MH (χ = 5.47, P = 0.019) there was a trend between success and lack of thick cellophane membrane (χ = 3.32, P = 0.068). Rate of posterior vitreous detachment was reduced with presence of diabetes mellitus (25%) and with thick cellophane membrane (50%). Mean follow-up time was 11.1 ± 9.9 months. Median baseline and last best spectacle-corrected visual acuities were 20/50 and 20/40, respectively (P < 0.001). Twenty-eight of 35 eyes (80.0%) with VMT only and all 15 eyes (100%) with a small Stage 2 MH developed a posterior vitreous detachment, with MH closure in 10 of 15 eyes (66.7%). A posterior vitreous detachment developed in 43 eyes (86.0%) after a single gas injection, at a median of 3.0 weeks. ![]() Patients with small MH maintained partial face-down positioning.įorty-nine consecutive patients (50 eyes) with symptomatic VMT underwent pneumatic vitreolysis between 20. Patients avoided the supine position until gas resolution. ![]() To evaluate the outcome of perfluoropropane (C3F8) gas injection for symptomatic vitreomacular traction (VMT) with or without Stage 2 macular hole (MH).Ī retrospective review of eyes with VMT treated with 0.3 mL of C3F8 gas was performed.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |